RE: Blowing of own trumpet29 Mar 2021 12:42
It was confirmed by John that you can't patent a target, i.e. tyk2 Catalytic. But tyk2 as a target is relatively new in the world of treatments, hence the importance on BMS progressing, it gives a sense of insurance to others that it's safe and it works.
As you read more about tyk2 you will discover it is inherently difficult to target the Catalytic site, a special set of skills (Taken style) are needed in molecule design. Tim and John are a small number of people with the skills to do this. BMS and Nimbus have gone a different route, we can only guess on the reasons but they won't admit a "too difficult" line, instead as Thoth has said, failure turned feature, but since tyk2 targeting is so new, this allosteric approach is good and looks like it will work. Although not as unique as they like to tell you.
Now we shouldn't be worried by these allosteric compounds, they are by nature only tyk2, when you look at the various disease profiles you will find that dual tyk2 and jak1 can be more beneficial for some indications.
Yet BMS and Nimbus will state jak1 targeting will cause unwanted side effects - that's to vague to mean anything really and approved drugs exist which only target jak1, but they are trying to capture a multi billion market first, so as mentioned they will blow their own trumpet.
I really don't understand Nimbus compound who are trying Allosteric, I don't think there is much benefit since it's only tyk2.
Because we have multiple compounds, with varying selectivity across the JAK profiles, as the research progresses it will become evident that a little bit of JAK1 will improve results in some indications. Unlucky BMS and Nimbus, and Tim will be proven right over Don Nicholson.
Now let's just enjoy the relaxed lockdown rules until we smash the bottle on Thoth's yacht.
Sign In
Follow the stocks
